Sumitomo Pharma Co., Ltd. (FRA:DPM)

Market Cap	3.51B +57.0%
Revenue (ttm)	2.47B +13.7%
Net Income	582.90M +352.2%
EPS	1.47 +352.2%
Shares Out	n/a
PE Ratio	6.03
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	7.85
Previous Close	7.97
Day's Range	7.85 - 7.85
52-Week Range	4.82 - 18.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 13, 2026

About Sumitomo Pharma

Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson’s disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has coll...

• Industry: Pharmaceutical Preparations
• Founded: 1897
• Employees: 3,832
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: DPM

Financial Performance

In fiscal year 2026, Sumitomo Pharma's revenue was 453.29 billion, an increase of 13.66% compared to the previous year's 398.83 billion. Earnings were 106.87 billion, an increase of 352.17%.

Financial numbers in JPY